Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
McKinsey
Harvard Business School
Deloitte
Johnson and Johnson
Boehringer Ingelheim
US Department of Justice
Citi
Express Scripts

Generated: May 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 5,684,189

« Back to Dashboard

Title: GABA and L-glutamic acid analogs for antiseizure treatment
Abstract:A compound of the formula ##STR1## wherein R.sub.1 is a straight or branched alkyl group having from 1 to 6 carbon atoms, phenyl, or cycloalkyl having from 3 to 6 carbon atoms; R.sub.2 is hydrogen or methyl; and R.sub.3 is hydrogen, methyl or carboxyl; which is useful in the treatment of seizure disorders. Processes are disclosed for the preparation of the compound. Intermediates prepared during the synthesis of the compound are also disclosed.
Inventor(s): Silverman; Richard B. (Morton Grove, IL), Andruszkiewicz; Ryszard (Sopot, PL), Yuen; Po-Wai (Ann Arbor, MI), Sobieray; Denis Martin (Holland, MI), Franklin; Lloyd Charles (Hamilton, MI), Schwindt; Mark Alan (Holland, MI)
Assignee: Northwestern University (Evanston, IL) Warner-Lambert Company (Ann Arbor, MI)
Filing Date:Apr 12, 1995
Application Number:08/420,576
Claims:1. A process for preparing an S-isomer of a compound of the formula

which comprises hydrolyzing an azide of the formula ##STR9## to an intermediate azide of the formula ##STR10## extracting the intermediate carboxylic acid azide into an aqueous base and reducing the intermediate azide the to the amine of the formula ##STR11## wherein Bn is benzyl.

2. A process as defined in claim 1 wherein the azide is a benzyl ester and is hydrolysed by treatment with sodium hydroxide.

3. A process as defined in claim 1 further comprising the step of acidifying the aqueous extract.

4. A process as defined in claim 1 wherein the intermediate carboxylic acid azide is reduced under near neutral conditions to give the amino acid.

5. A process for preparing an S-isomer of a compound of the formula ##STR12## which comprises hydrolyzing an azide of the formula ##STR13## to an intermediate azide of the formula ##STR14## extracting the intermediate carboxylic acid azide into an aqueous base and reducing the intermediate azide the to the amine of the formula ##STR15##

6. A process as defined in claim 5 wherein the azide is a t-butyl ester and is hydrolysed by treatment with aqueous formic acid.

7. A process as defined in claim 5 further comprising the step of acidifying the aqueous extract.

8. A process as defined in claim 5 wherein the intermediate carboxylic acid azide is reduced under near neutral conditions to give the amino acid.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Farmers Insurance
US Department of Justice
Merck
Mallinckrodt
US Army
Federal Trade Commission
Boehringer Ingelheim
Johnson and Johnson
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.